Objective
The need: Today, although over 6M people suffer from Parkinson's and related diseases worldwide we have no objective early diagnostic test. By the time patients present the symptoms that lead to diagnosis the disease is already very advanced and the options for treatment extremely limited. This has an enormous impact on cost of care and an even greater impact on patient and carer quality of life. An early diagnostic test will revolutionise treatment in terms of slowing disease evolution and improved outcomes, with fewer years in the advanced phases of the disease requiring expensive full-time care.
Our goal: We aim to commercialise non-invasive, very low-cost preclinical electroencephalograph (EEG) biomarkers for synucleinopathies (Parkinson Disease - PD and Lewy Body Dementia - LBD), which will have real impact on both quality of life and cost of care.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesbasic medicineneurologydementia
- medical and health sciencesbasic medicineneurologyparkinson
You need to log in or register to use this function
Programme(s)
Topic(s)
Call for proposal
(opens in new window) H2020-SMEInst-2014-2015
See other projects for this callSub call
H2020-SMEINST-1-2014
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
08035 Barcelona
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.